ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 4.2% in the third quarter, HoldingsChannel reports. The institutional investor owned 425,225 shares of the specialty pharmaceutical company’s stock after buying an additional 17,314 shares during the quarter. Geode Capital Management LLC’s holdings in ANI Pharmaceuticals were worth $25,373,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Texas Permanent School Fund Corp increased its stake in ANI Pharmaceuticals by 1.3% in the 2nd quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock valued at $852,000 after purchasing an additional 178 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in ANI Pharmaceuticals by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after purchasing an additional 200 shares during the last quarter. Arizona State Retirement System increased its position in shares of ANI Pharmaceuticals by 4.7% in the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after buying an additional 211 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after buying an additional 299 shares during the last quarter. Finally, New York State Teachers Retirement System raised its stake in shares of ANI Pharmaceuticals by 1.7% during the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock worth $1,439,000 after buying an additional 394 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on ANIP. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective on the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. Finally, Raymond James raised their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $77.71.

Insider Activity

In related news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the sale, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,231 shares of company stock valued at $2,434,286 in the last 90 days. 12.70% of the stock is currently owned by insiders.

ANI Pharmaceuticals Stock Down 2.0 %

ANIP stock opened at $54.41 on Friday. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $70.81. The stock has a market capitalization of $1.14 billion, a P/E ratio of -98.93 and a beta of 0.73. The company has a 50 day moving average price of $57.48 and a two-hundred day moving average price of $59.68. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the previous year, the business earned $1.05 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.